David Amsellem
Stock Analyst at Piper Sandler
(0.1)
# 2088
Out of 5,240 analysts
168
Total ratings
48.08%
Success rate
3.85%
Average return
Main Sectors:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Intra-Cellular Thera... | Downgrades: Neutral | 107 132 | 126.84 | 4.07% | 1 | Jan 14, 2025 | |
Avadel Pharmaceutica... | Maintains: Overweight | 24 13 | 8.03 | 61.89% | 5 | Jan 10, 2025 | |
Sage Therapeutics | Maintains: Overweight | 26 9 | 7.46 | 20.64% | 1 | Jan 2, 2025 | |
Amgen | Maintains: Overweight | 344 310 | 267 | 16.1% | 1 | Jan 2, 2025 | |
Neurocrine Bioscienc... | Reiterates: Overweight | 160 160 | 139.49 | 14.7% | 8 | Dec 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 163 163 | 123.1 | 32.41% | 9 | Dec 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 13 14 | 11.71 | 19.56% | 6 | Dec 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 15 | 5.02 | 198.8% | 2 | Nov 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 11 | 7.86 | 39.95% | 4 | Nov 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 3 3 | 3.21 | -6.54% | 4 | Nov 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 38 37 | 28.5 | 29.82% | 7 | Oct 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 15 16 | 11.23 | 42.48% | 4 | Oct 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 37 37 | 33.15 | 11.61% | 6 | Oct 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 68 | 54.22 | 25.41% | 1 | Oct 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 38 67 | 51.62 | 29.79% | 5 | Sep 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 41 36 | 37.85 | -4.89% | 12 | Sep 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 6 | 3.29 | 82.37% | 8 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 71 66 | 38.47 | 71.56% | 5 | Aug 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 9 3 | 7.47 | -59.84% | 7 | Aug 2, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 42 42 | 20.55 | 104.38% | 7 | Jul 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 19 20 | 21 | -4.76% | 9 | May 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22 24 | 15.84 | 51.52% | 5 | Apr 29, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 10 | 3.04 | 228.95% | 1 | Apr 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 21 | 3.65 | 475.34% | 3 | Feb 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 90 113 | 84.66 | 33.48% | 3 | Jan 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 33 45 | n/a | n/a | 2 | Dec 7, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 144 12 | 4.71 | 154.78% | 3 | Nov 14, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 72 42 | 36.42 | 15.32% | 3 | Oct 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 26 17 | 0.65 | 2515.38% | 3 | Aug 9, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 285 | n/a | n/a | 1 | Jan 5, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 90 110 | n/a | n/a | 5 | Dec 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 3750 250 | n/a | n/a | 2 | May 25, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 6 | n/a | n/a | 2 | Apr 14, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 5 3 | n/a | n/a | 5 | Mar 2, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 5 6 | n/a | n/a | 2 | Feb 15, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 7 8 | n/a | n/a | 1 | Oct 12, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 23 17 | n/a | n/a | 1 | Apr 15, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 9 | n/a | n/a | 4 | Oct 17, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Mar 9, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 2 | Jul 18, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 5 | May 10, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 12 | n/a | n/a | 1 | Dec 19, 2016 |